New approaches to design HIV-1 T-cell vaccines

Current Opinion in HIV and AIDS

Volumn 5, Issue 5, 2010, Pages 368-376

  Perrin, Hélène ^a   Canderan, Glenda ^a   Sékaly, Rafick Pierre ^a,b   Trautmann, Lydie ^a  

^a Vaccine and Gene Therapy Institute Florida (VGTI FL)   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

dendritic cell targeting; HIV 1 vaccine; protective T cell

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN SPECIFICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL HOMING; CLINICAL TRIAL; DRUG DESIGN; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; INNATE IMMUNITY; MUCOSA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

AIDS VACCINES; HIV INFECTIONS; HIV-1; HUMANS; SYSTEMS BIOLOGY; T-LYMPHOCYTES;

EID: 77955512306     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833d2cc0     Document Type: Review

References (132)

1. WHO. 2009 global summary. http://www.who.int/hiv/data/2009-global- summary.gif.
2. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
3. Shen L, Peterson S, Sedaghat AR, et al. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766.
4. Berkley SF, Koff WC. Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007; 370:94-101.
5. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.
6. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
7. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413-444.
8. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
9. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
10. Watkins DI, Burton DR, Kallas EG, et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14:617-621.
11. Stranford SA, Skurnick J, Louria D, et al. Lack of infection in HIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. Proc Natl Acad Sci U S A 1999; 96:1030-1035.
12. Clerici M, Salvi A, Trabattoni D, et al. A role for mucosal immunity in resistance to HIV infection. Immunol Lett 1999; 66:21-25.
13. Fowke KR, Nagelkerke NJ, Kimani J, et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996; 348:1347-1351.
14. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64.
15. Cohen J. AIDS vaccine research. HIV natural resistance field finally overcomes resistance. Science 2009; 326:1476-1477.
16. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283:857-860.
17. Reynolds MR, Rakasz E, Skinner PJ, et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 2005; 79:9228-9235.
18. Li Q, Skinner PJ, Ha SJ, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726-1729.
19. Wilson NA, Reed J, Napoe GS, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006; 80:5875-5885.
20. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
21. Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
22. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-459.
23. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The firstT cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009; 206:1253-1272.
24. Goulder PJ, Altfeld MA, Rosenberg ES, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001; 193:181-194.
25. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289.
26. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555.
27. Hansen SG, Vieville C, Whizin N, et al. Effector memoryT cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-299.
28. Brandler S, Lepelley A, Desdouits M, et al. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 2010; 84:5314-5328.
29. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91.
30. Barouch DH, Korber B. HIV-1 vaccine development after STEP. Annu Rev Med 2010; 61:153-167.
31. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
32. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007; 318:28-29.
33. Corey L, McElrath MJ, Kublin JG. Poststep modifications for research on HIV vaccines. AIDS 2009; 23:3-8.
34. Hutnick NA, Carnathan DG, Dubey SA, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009; 15:876-878.
35. O'Brien KL, Liu J, King SL, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009; 15:873-875.
36. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
37. Cohen J. HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine 'success'. Science 2009; 326:652-653.
38. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-619.
39. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464:224-231.
40. O'Connor DH, Allen TM, Vogel TU, et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002; 8:493-499.
41. Hu SL, Abrams K, Barber GN, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255:456-459.
42. Kawashima Y, Pfafferott K, Frater J, et al. Adaptation of HIV-1 to human leukocyte antigen class I. Nature 2009; 458:641-645.
43. Martins MA, Wilson NA, Reed JS, et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 2010; 84:4352-4365.
44. Kiepiela P, Ngumbela K, Thobakgale C, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.
45. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354-2360.
46. Fischer W, Perkins S,Theiler J, et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007; 13:100106.
47. Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26: 3947-3957.
48. Barouch DH, O'Brien KL, Simmons NL, et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010; 16:319-323.
49. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-328.
50. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008; 105:3849-3854.
51. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008; 14:623-628.
52. Kastenmuller W, Gasteiger G, Gronau JH, et al. Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination. J Exp Med 2007; 204:2187-2198.
53. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119-3131.
54. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-125.
55. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009; 9:741-747.
56. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278:1447-1450.
57. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034-1038.
58. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-98.
59. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007; 110:1916-1923.
60. Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 2004; 55:355-372.
61. Feinberg MB, Moore JP. AIDS vaccine models: challenging challenge viruses. Nat Med 2002; 8:207-210.
62. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ Tcell responses. J Exp Med 2007; 204:1405-1416.
63. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory. CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008; 28:710-722.
64. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
65. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
66. Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203:2281-2292.
67. Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009; 183:7919-7930.
68. Co MD, Kilpatrick ED, Rothman AL. Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization. Immunology 2009; 128 (Suppl 1):e718-e727.
69. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
70. Emu B, Sinclair E, Favre D, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-14178.
71. Migueles SA, Sabbaghian MS, Shupert WL, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:27092714.
72. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104: 6776-6781.
73. Owen RE, Heitman JW, Hirschkorn DF, et al. HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 2010; 24:1095-1105.
74. Duvall MG, Precopio ML, Ambrozak DA, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008; 38:350363.
75. Casimiro D, McElrath J. The STEP trial: a pathway toward understanding the biological basis for the vaccine efficacy results. http://www.hvtn.org/fgm/ 1107slides/McElrath.pdf.
76. Almeida JR, Price DA, Papagno L, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204:2473-2485.
77. Belyakov IM, Kuznetsov VA, Kelsall B, et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006; 107:3258-3264.
78. Betts MR, Harari A. Phenotype and function of protective T cell immune responses in HIV. Curr Opin HIV AIDS 2008; 3:349-355.
79. Almeida JR, Sauce D, Price DA, et al. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. Blood 2009; 113:6351-6360.
80. Brown SA, Surman SL, Sealy R, et al. Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials. Viruses 2010; 2:435467.
81. Harari A, Bart PA, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008; 205:63-77.
82. Estcourt MJ, Ramsay AJ, Brooks A, et al. Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 2002; 14:31-37.
83. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 2008; 28:859-869.
84. Schmidt NW, Podyminogin RL, Butler NS, et al. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A 2008; 105:14017-14022.
85. Castellino F, Galli G, Del Giudice G, et al. Generating memory with vaccination. Eur J Immunol 2009; 39:2100-2105.
86. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17:326-332.
87. Wherry EJ,TeichgraberV, BeckerTC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4:225-234.
88. Vezys V, Yates A, Casey KA, et al. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 2009; 457:196-199.
89. Cockburn IA, Chen YC, Overstreet MG, et al. Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog 2010; 6:e1000877.
90. Grandpre LE, Duke-Cohan JS, Ewald BA, et al. Immunogenicity of recombi-nant modified vaccinia ankara following a single or multidose vaccine regimen in rhesus monkeys. Vaccine 2009; 27:1549-1556.
91. Flatz L, Hegazy AN, Bergthaler A, et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+T cell immunity. Nat Med 2010; 16:339-345.
92. Aboud S, Nilsson C, Karlen K, et al. Strong HIV-Specific CD4+ and CD8+ T lymphocyte proliferative responses in healthy individuals immunized with a HIV-1 DNA vaccine and boosted with HIV-1 recombinant modified vaccinia virus Ankara (MVA). Clin Vaccine Immunol 2010; doi:001.1128/CUI.0008-10.
93. Garber DA, O'Mara LA, Zhao J, et al. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies. PLoS One 2009; 4:e5445.
94. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533.
95. Harari A, Pantaleo G. Understanding what makes a good versus a bad vaccine. Eur J Immunol 2005; 35:2528-2531.
96. Petrovas C, Chaon B, Ambrozak DR, et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. J Immunol 2009; 183:1120-1132.
97. Mueller YM, Petrovas C, Do DH, et al. Early establishment and antigen dependence of simian immunodeficiency virus-specific CD8+ T-cell defects. J Virol 2007; 81:10861-10868.
98. Whitmire JK, Eam B, Whitton JL. Tentative T cells: memory cells are quickto respond, but slow to divide. PLoS Pathog 2008; 4:e1000041.
99. Masopust D. Developing an HIV cytotoxic T-lymphocyte vaccine: issues of. CD8 T-cell quantity, quality and location. J Intern Med 2009; 265:125-137.
100. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291:2413-2417.
101. Greene JM, Lhost JJ, Burwitz BJ, et al. Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vacci- nated macaques suppress SIVmac239 replication ex vivo. J Virol 2010; 84:3362-3372.
102. Holst PJ, Orskov C, Thomsen AR, et al. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 2010; 184:4431-4439.
103. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.
104. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007; 37 (Suppl 1):S53-S60.
105. Daniel MD, Kirchhoff F, Czajak SC, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938-1941.
106. BabaTW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5:194-203.
107. QuerecT, BennounaS, Alkan S, et al. Yellowfevervaccine YF-17Dactivates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203:413-424.
108. Lau LL, Jiang J, Shen H. In vivo modulation of T cell responses and protective immunity by TCR antagonism during infection. J Immunol 2005; 174:79707976.
109. Lore K, Betts MR, Brenchley JM, et al. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific T cell responses. J Immunol 2003; 171:4320-4328.
110. Storni T, Ruedl C, Renner WA, et al. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol 2003; 171:795-801.
111. Wille-Reece U, Wu CY, Flynn BJ, et al. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005; 174:7676-7683.
112. Wille-Reece U, Flynn BJ, Lore K, et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006; 203:1249-1258.
113. Longhi MP, Trumpfheller C, Idoyaga J, et al. Dendritic cells require a systemic. type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206:1589-1602.
114. Bahl K, Kim SK, Calcagno C, et al. IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J Immunol 2006; 176:4284-4295.
115. Thompson LJ, Kolumam GA, Thomas S, et al. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J Immunol 2006; 177:1746-1754.
116. McGill J, Van Rooijen N, Legge KL. IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J Exp Med 2010; 207:521-534.
117. Zhang B, Zhang Y, Niu L, et al. Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death. J Immunol 2010; 184:4770-4778.
118. Engelmayer J, Larsson M, Lee A, et al. Mature dendritic cells infected with canarypox virus elicit strong antihuman immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 2001; 75:2142-2153.
119. Zhang R, Zhang S, Li M, et al. Incorporation of CD40 ligand into SHIV viruslike particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. Vaccine 2010; doi:10.1016/j.vac-cine. 2010.03.079.
120. Trumpfheller C, Finke JS, Lopez CB, et al. Intensified and protective CD4+ T cell immunity in mice with antidendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006; 203:607-617.
121. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008; 205:2717-2725.
122. Britten CM, Janetzki S, Ben-Porat L, et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 2009; 58:1701-1713.
123. Britten CM, Janetzki S, van der Burg SH, et al. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol Immunother 2008; 57:285-288.
124. Janetzki S, Britten CM, Kalos M, et al. "MIATA"-minimal information aboutT cell assays. Immunity 2009; 31:527-528.
125. Kallies A. Distinct regulation of effector and memory T-cell differentiation. Immunol Cell Biol 2008; 86:325-332.
126. Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 2010; 115:1678-1689.
127. Hladik F, Sakchalathorn P, Ballweber L, et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 2007; 26:257-270.
128. Randolph GJ, Beaulieu S, LebecqueS, et al. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 1998; 282:480-483.
129. Zak DE, Aderem A. Systems biology of innate immunity. Immunol Rev 2009; 227:264-282.
130. Gardy JL, Lynn DJ, Brinkman FS, et al. Enabling a systems biology approach to immunology: focus on innate immunity. Trends Immunol 2009; 30:249262.
131. AVAC. Ongoing trials of preventive HIV/AIDS vaccines worldwide. www. avac.org/trials-table.htm; 2009.
132. Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009; 326:285-289.